A Study of BH-30236
Phase 1
170
about 3 years
18+
13 sites in CA, FL, IL +6
About this study
Researchers are testing a new medication called BH-30236 in people with relapsed or refractory acute myelogenous leukemia (AML) or higher-risk myelodysplastic syndrome (MDS). The trial will evaluate the safety and how well the medication works, as well as its effects on the body.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BH-30236
- 2.Take Venetoclax
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
venetoclax
oral
Primary: Dose Escalation and Expansion: Safety evaluation of BH-30236: Number of participants with treatment-related adverse events as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Dose Expansion: Composite Complete Remission (CR) Rate
Secondary: Dose Escalation and Expansion: Complete remission (CR) / complete remission with partial hematologic recovery (CRh) rate for AML and complete remission/partial remission (CR/PR) rate for HR-MDS, Dose Escalation and Expansion: Duration of Response (DoR), Dose Escalation and Expansion: Maximum observed blood concentration (Cmax) of BH-30236., Dose Escalation and Expansion: Objective Response Rate (ORR), Dose Escalation and Expansion: Relapse-free Survival (RFS), Dose Escalation: Area under the blood concentration time curve (AUC) of BH-30236.
Oncology